These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9302186)

  • 1. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update.
    Walsh PC
    J Urol; 1997 Oct; 158(4):1618-9. PubMed ID: 9302186
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer--a multi-institutional update].
    Graefen M
    Aktuelle Urol; 2004 Sep; 35(5):377-8. PubMed ID: 15384003
    [No Abstract]   [Full Text] [Related]  

  • 3. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
    Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
    J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
    Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
    J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical stage, prostate-specific antigen and Gleason grade to predict extracapsular disease or nodal metastasis in men with newly diagnosed, previously untreated prostate cancer. A multicenter study. A. Ur. O. Cooperative Group.
    Puppo P; Perachino M
    Eur Urol; 1997; 32(3):273-9. PubMed ID: 9358212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Stenman UH
    Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of percent free prostate specific antigen for staging clinically localized prostate cancer.
    Pannek J; Rittenhouse HG; Chan DW; Epstein JI; Walsh PC; Partin AW
    J Urol; 1998 Apr; 159(4):1238-42. PubMed ID: 9507844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
    Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B
    J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Nishimoto K; Nakashima J; Hashiguchi A; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M; Murai M
    Int J Urol; 2008 Jun; 15(6):520-3. PubMed ID: 18422574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.
    Whittemore DE; Hick EJ; Carter MR; Moul JW; Miranda-Sousa AJ; Sexton WJ
    J Urol; 2008 Feb; 179(2):516-22; discussion 522. PubMed ID: 18076949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multivariate models as predictors of pathological stage using Gleason score, clinical stage, and serum prostate-specific antigen.
    Polascik TJ; Pearson JD; Partin AW
    Semin Urol Oncol; 1998 Aug; 16(3):160-71. PubMed ID: 9741421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
    Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
    J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
    Jones TD; Koch MO; Lin H; Cheng L
    BJU Int; 2005 Dec; 96(9):1253-7. PubMed ID: 16287440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prediction of the stage of patients with prostate cancer by the combination of serum prostate specific antigen and Gleason score].
    Song G; Zhou LQ; He ZS; Li NC; Li M; Hao JR; Pan BN; Na YQ
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):376-8. PubMed ID: 16638345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.